10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 10-Q
(Mark One)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended December 31, 2007
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number 000-06516
DATASCOPE CORP.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
13-2529596 |
|
(State of other jurisdiction of
|
|
(I.R.S. Employer Identification No.) |
incorporation or organization) |
|
|
|
|
|
14 Philips Parkway, Montvale, New Jersey
|
|
07645-9998 |
|
(Address of principal executive offices)
|
|
(Zip Code) |
(201) 391-8100
(Registrants telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by
Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. YES þ NO o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller
reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large Accelerated filer o Accelerated filer þ Non-accelerated filer o Smaller reporting company o
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). YES o NO þ
Number of Shares of Companys Common Stock outstanding as of January 31, 2008: 15,440,738.
Datascope Corp.
Form 10-Q Index
|
|
|
|
|
|
|
Page |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
|
|
2 |
|
|
|
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
4-20 |
|
|
|
|
|
|
|
|
|
21-30 |
|
|
|
|
|
|
|
|
|
30 |
|
|
|
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32 |
|
|
|
|
|
|
|
|
|
32 |
|
|
|
|
|
|
|
|
|
33 |
|
|
|
|
|
|
|
|
|
33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit 31.1. Certification of Principal Executive Officer Regarding Facts
and Circumstances Relating to Quarterly Reports |
|
|
|
|
|
Exhibit 31.2. Certification of Principal Financial Officer Regarding Facts
and Circumstances Relating to Quarterly Reports |
|
|
|
|
|
Exhibit 32.1. Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
EX-31.1: CERTIFICATION |
EX-31.2: CERTIFICATION |
EX-32.1: CERTIFICATION |
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Datascope Corp. and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
June 30, |
|
|
|
2007 |
|
|
2007 |
|
|
|
(Unaudited) |
|
|
(a) |
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
17,396 |
|
|
$ |
15,780 |
|
Short-term investments |
|
|
25,399 |
|
|
|
23,681 |
|
Accounts receivable less allowance for
doubtful accounts of $2,207 and $2,603 |
|
|
92,225 |
|
|
|
85,553 |
|
Inventories |
|
|
62,349 |
|
|
|
59,455 |
|
Prepaid income taxes |
|
|
|
|
|
|
2,293 |
|
Prepaid expenses and other current assets |
|
|
12,041 |
|
|
|
11,167 |
|
Current deferred taxes |
|
|
7,268 |
|
|
|
7,238 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
216,678 |
|
|
|
205,167 |
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net of accumulated
depreciation of $105,757 and $100,760 |
|
|
83,928 |
|
|
|
82,812 |
|
Long-term investments |
|
|
15,415 |
|
|
|
14,346 |
|
Intangible assets, net |
|
|
25,681 |
|
|
|
26,074 |
|
Goodwill |
|
|
13,595 |
|
|
|
12,860 |
|
Other assets |
|
|
36,560 |
|
|
|
34,897 |
|
|
|
|
|
|
|
|
|
|
$ |
391,857 |
|
|
$ |
376,156 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
29,203 |
|
|
$ |
18,386 |
|
Dividends payable |
|
|
|
|
|
|
1,532 |
|
Accrued expenses |
|
|
13,895 |
|
|
|
16,129 |
|
Accrued compensation |
|
|
14,221 |
|
|
|
17,422 |
|
Deferred revenue |
|
|
4,079 |
|
|
|
4,380 |
|
Income taxes payable |
|
|
6,030 |
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
67,428 |
|
|
|
57,849 |
|
Other liabilities |
|
|
26,943 |
|
|
|
25,220 |
|
Commitments and contingencies (Note 11) |
|
|
|
|
|
|
|
|
Stockholders equity: |
|
|
|
|
|
|
|
|
Preferred stock, par value $1.00 per share: |
|
|
|
|
|
|
|
|
Authorized 5,000 shares; Issued, none |
|
|
|
|
|
|
|
|
Common stock, par value $0.01 per share: |
|
|
|
|
|
|
|
|
Authorized, 45,000 shares;
Issued, 18,952 and 18,867 shares |
|
|
189 |
|
|
|
189 |
|
Additional paid-in capital |
|
|
110,587 |
|
|
|
109,384 |
|
Treasury stock at cost, 3,521 shares |
|
|
(107,037 |
) |
|
|
(107,037 |
) |
Retained earnings |
|
|
293,843 |
|
|
|
294,765 |
|
Accumulated other comprehensive loss: |
|
|
|
|
|
|
|
|
Cumulative translation adjustments |
|
|
5,501 |
|
|
|
1,899 |
|
Benefit plan adjustments |
|
|
(5,683 |
) |
|
|
(5,827 |
) |
Unrealized gain (loss) on available-for-sale securities |
|
|
86 |
|
|
|
(286 |
) |
|
|
|
|
|
|
|
Total stockholders equity |
|
|
297,486 |
|
|
|
293,087 |
|
|
|
|
|
|
|
|
|
|
$ |
391,857 |
|
|
$ |
376,156 |
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
Derived from audited consolidated financial statements. |
See notes to unaudited condensed consolidated financial statements.
1
Datascope Corp. and Subsidiaries
Condensed Consolidated Statements of Earnings
(In thousands, except per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
Three Months Ended |
|
|
|
December 31, |
|
|
December 31, |
|
|
|
2007 |
|
|
2006 |
|
|
2007 |
|
|
2006 |
|
Net sales |
|
$ |
190,700 |
|
|
$ |
182,800 |
|
|
$ |
103,400 |
|
|
$ |
95,600 |
|
Cost of sales |
|
|
84,189 |
|
|
|
80,212 |
|
|
|
45,092 |
|
|
|
42,979 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
106,511 |
|
|
|
102,588 |
|
|
|
58,308 |
|
|
|
52,621 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
expenses |
|
|
18,607 |
|
|
|
17,197 |
|
|
|
9,567 |
|
|
|
8,543 |
|
Selling, general and
administrative
expenses |
|
|
71,608 |
|
|
|
70,129 |
|
|
|
38,128 |
|
|
|
34,956 |
|
Special charges |
|
|
|
|
|
|
7,309 |
|
|
|
|
|
|
|
7,309 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90,215 |
|
|
|
94,635 |
|
|
|
47,695 |
|
|
|
50,808 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating earnings |
|
|
16,296 |
|
|
|
7,953 |
|
|
|
10,613 |
|
|
|
1,813 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (income) expense: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
(1,102 |
) |
|
|
(1,341 |
) |
|
|
(493 |
) |
|
|
(613 |
) |
Interest expense |
|
|
86 |
|
|
|
65 |
|
|
|
18 |
|
|
|
36 |
|
Dividend income |
|
|
|
|
|
|
(196 |
) |
|
|
|
|
|
|
(196 |
) |
Gain on sale of
investment |
|
|
(13,173 |
) |
|
|
(1,273 |
) |
|
|
|
|
|
|
(1,273 |
) |
Other, net |
|
|
251 |
|
|
|
224 |
|
|
|
182 |
|
|
|
131 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(13,938 |
) |
|
|
(2,521 |
) |
|
|
(293 |
) |
|
|
(1,915 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before income
taxes |
|
|
30,234 |
|
|
|
10,474 |
|
|
|
10,906 |
|
|
|
3,728 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes |
|
|
11,353 |
|
|
|
2,606 |
|
|
|
3,817 |
|
|
|
393 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings |
|
$ |
18,881 |
|
|
$ |
7,868 |
|
|
$ |
7,089 |
|
|
$ |
3,335 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share,
basic |
|
$ |
1.23 |
|
|
$ |
0.52 |
|
|
$ |
0.46 |
|
|
$ |
0.22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of common
shares outstanding,
basic |
|
|
15,350 |
|
|
|
15,213 |
|
|
|
15,354 |
|
|
|
15,205 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share, diluted |
|
$ |
1.22 |
|
|
$ |
0.51 |
|
|
$ |
0.46 |
|
|
$ |
0.22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of common
shares outstanding,
diluted |
|
|
15,496 |
|
|
|
15,472 |
|
|
|
15,515 |
|
|
|
15,488 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash dividends
declared per common
share |
|
$ |
1.10 |
|
|
$ |
1.17 |
|
|
$ |
|
|
|
$ |
0.07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to unaudited condensed consolidated financial statements.
2
Datascope Corp. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
December 31, |
|
|
|
2007 |
|
|
2006 |
|
Operating Activities: |
|
|
|
|
|
|
|
|
Net earnings |
|
$ |
18,881 |
|
|
$ |
7,868 |
|
Adjustments to reconcile net earnings to net
cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation |
|
|
7,225 |
|
|
|
7,602 |
|
Amortization |
|
|
3,069 |
|
|
|
2,936 |
|
Provision for supplemental pension and post-retirement medical |
|
|
685 |
|
|
|
651 |
|
Provision for (gains) losses on accounts receivable |
|
|
(37 |
) |
|
|
184 |
|
Cash surrender value of officers life insurance |
|
|
(129 |
) |
|
|
(192 |
) |
Realized gain on sale of investment |
|
|
(13,173 |
) |
|
|
(1,273 |
) |
Stock-based compensation expense |
|
|
557 |
|
|
|
360 |
|
Excess tax benefits on stock-based compensation |
|
|
(61 |
) |
|
|
(93 |
) |
Deferred income tax (benefit) expense |
|
|
(61 |
) |
|
|
493 |
|
Special charges asset write-offs |
|
|
|
|
|
|
365 |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(4,642 |
) |
|
|
2,348 |
|
Inventories |
|
|
(5,041 |
) |
|
|
(4,345 |
) |
Prepaid expenses and other assets |
|
|
2,079 |
|
|
|
413 |
|
Accounts payable |
|
|
10,733 |
|
|
|
(1,188 |
) |
Income taxes payable |
|
|
7,165 |
|
|
|
|
|
Accrued and other liabilities |
|
|
(9,264 |
) |
|
|
(2,168 |
) |
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
17,986 |
|
|
|
13,961 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing Activities: |
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
(4,188 |
) |
|
|
(2,673 |
) |
Purchases of investments |
|
|
(40,178 |
) |
|
|
(52,221 |
) |
Proceeds from investment maturities |
|
|
33,123 |
|
|
|
47,237 |
|
Proceeds from investment sales |
|
|
18,255 |
|
|
|
17,766 |
|
Capitalized software |
|
|
(3,828 |
) |
|
|
(4,005 |
) |
Purchased technology and licenses |
|
|
(13 |
) |
|
|
(109 |
) |
|
|
|
|
|
|
|
Net cash provided by investing activities |
|
|
3,171 |
|
|
|
5,995 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Activities: |
|
|
|
|
|
|
|
|
Exercise of stock options |
|
|
448 |
|
|
|
947 |
|
Treasury shares acquired under repurchase programs |
|
|
|
|
|
|
(1,718 |
) |
Excess tax benefits on stock-based compensation |
|
|
61 |
|
|
|
93 |
|
Cash dividends paid |
|
|
(18,490 |
) |
|
|
(17,364 |
) |
Guaranteed milestone payments |
|
|
(500 |
) |
|
|
(500 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities |
|
|
(18,481 |
) |
|
|
(18,542 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rates on cash |
|
|
(1,060 |
) |
|
|
(423 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase in cash and cash equivalents |
|
|
1,616 |
|
|
|
991 |
|
Cash and cash equivalents, beginning of period |
|
|
15,780 |
|
|
|
9,479 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of period |
|
$ |
17,396 |
|
|
$ |
10,470 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental Cash Flow Information |
|
|
|
|
|
|
|
|
Cash paid during the period for: |
|
|
|
|
|
|
|
|
Income taxes paid |
|
$ |
7,023 |
|
|
$ |
4,324 |
|
|
|
|
|
|
|
|
Income taxes refunded |
|
$ |
3,724 |
|
|
$ |
3,526 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash investing and financing activities: |
|
|
|
|
|
|
|
|
Net transfers of inventory to fixed assets
for use as demonstration equipment |
|
$ |
3,716 |
|
|
$ |
2,992 |
|
|
|
|
|
|
|
|
Dividends declared, not paid |
|
$ |
|
|
|
$ |
1,526 |
|
|
|
|
|
|
|
|
See notes to unaudited condensed consolidated financial statements.
3
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited, in thousands except per share data)
1. Summary of Significant Accounting Policies
The accompanying unaudited condensed consolidated financial statements include the accounts of
Datascope Corp. and its subsidiaries (the Company which may be referred to as our, us or
we). These statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (U.S. GAAP) for interim information, and with the
instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of
the information and footnotes required by U.S. GAAP for complete financial statements. In the
opinion of management, all adjustments (consisting of normal recurring adjustments) considered
necessary for a fair presentation have been included. Operating results for interim periods are not
necessarily indicative of results that may be expected for the full year. The presentation of
certain prior year information has been reclassified to conform with the current year presentation.
The consolidated statements of earnings for the three and six months ended December 31, 2006
includes an adjustment of $90 thousand and $199 thousand, respectively, from selling, general and
administrative expenses to cost of sales due to a correction of an error related to the
classification of inventory purchase discounts in fiscal 2007 that was not considered material.
Preparation of the Companys financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts in the financial statements and
accompanying notes. Actual results could differ from those estimates. For further information,
refer to the consolidated financial statements and notes included in the Companys Annual Report on
Form 10-K for the fiscal year ended June 30, 2007.
Recently Adopted Accounting Pronouncements
On July 1, 2007, we adopted the provisions of the Financial Accounting Standards Board (FASB)
Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN 48), an interpretation of
Statement of Financial Accounting Standards (SFAS) No. 109, Accounting for Income Taxes. FIN 48
clarifies the accounting for uncertainty in income taxes by prescribing that a benefit cannot be
recorded in the financial statements unless the tax position has a more likely than not chance of
being sustained upon audit based solely on the technical merits of the position. Once the more
likely than not standard is met, the benefit is measured by determining the amount that is greater
than 50 percent likely of being realized upon settlement, presuming that the tax position is
examined by the appropriate taxing authority that has full knowledge of all relevant information.
FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting
in interim periods, disclosure and transition. See Note 13 for additional information related to
the impact of adopting FIN 48.
4
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
1. Summary of Significant Accounting Policies (Continued)
Recent Accounting Pronouncements, Not Required to be Adopted as of December 31, 2007
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. SFAS 157 defines fair
value as: the price that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants at the measurement date. In addition, SFAS 157
establishes a fair value hierarchy to be used to classify the source of information used in fair
value measurements, new disclosures of assets and liabilities measured at fair value based on their
level in the hierarchy and a modification of the long-standing accounting presumption that the
transaction price of an asset or liability equals its initial fair value. SFAS 157 is effective for
fiscal years beginning after November 15, 2007 (our fiscal year 2009 beginning July 1, 2008). The
FASB has proposed a deferral of the provisions of SFAS 157 relating to nonfinancial assets and
liabilities that would delay implementation by us until our fiscal year 2010 beginning July 1,
2009. SFAS 157 is not expected to materially affect how we determine fair value, but may result in
certain additional disclosures.
In November 2006, the FASB issued Emerging Issues Task Force Issue No. 06-10, Accounting for
Deferred Compensation and Postretirement Benefits Aspects of Collateral Assignment Split-Dollar
Life Insurance Arrangements, which is effective for fiscal years that begin after December 15, 2007
(our fiscal year 2009 beginning July 1, 2008). The Task Force concluded that an employer should
recognize a liability for the postretirement benefit related to a collateral assignment
split-dollar life insurance arrangement in accordance with either FASB Statement No. 106,
Employers Accounting for Postretirement Benefits Other Than Pensions, or Accounting Principles
Board Opinion No. 12, Omnibus Opinion, based on the substantive agreement with the employee. The
Task Force also concluded that an employer should recognize and measure an asset based on the
nature and substance of the collateral assignment split-dollar life insurance arrangement. The
Supplemental Benefits Plan for the Chairman and Chief Executive Officer, Mr. Lawrence Saper,
provides survivor benefits in the form of a $10 million life insurance policy, maintained pursuant
to a collateral assignment split-dollar agreement among Mr. Saper, the Company and a trust for the
benefit of Mr. Sapers family. The present value of the premium reimbursement pursuant to the
split-dollar agreement at December 31, 2007 is approximately $3.4 million.
Upon adoption, we will record a liability and a cumulative effect adjustment to
retained earnings for the present value of the premium reimbursement at the date of
adoption.
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and
Financial Liabilities Including an amendment of FASB Statement No. 115. This statement provides
an option to report selected financial assets and liabilities at fair value. In addition, SFAS 159
establishes presentation and disclosure requirements for those assets and liabilities which the
registrant has chosen to measure at fair value. SFAS 159 is effective for fiscal years beginning
after November 15, 2007 (our fiscal year 2009 beginning July 1, 2008). We are currently evaluating
the impact of adopting SFAS 159 on our consolidated financial statements.
In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial
Statements an amendment of ARB No. 51. This statement amends ARB 51 to establish accounting and
reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of
a subsidiary. SFAS 160 clarifies a noncontrolling interest in a subsidiary is an ownership interest
in the consolidated entity that should be reported as equity in the consolidated financial
statements. SFAS 160 is effective for fiscal years beginning on or after December 15, 2008 (our
fiscal year 2010 beginning July 1, 2009). We are currently evaluating the impact of adopting SFAS
160 on our consolidated financial statements.
5
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
1. Summary of Significant Accounting Policies (Continued)
Recent Accounting Pronouncements, Not Required to be Adopted as of December 31, 2007 (Continued)
In December 2007, the FASB issued SFAS No. 141(R), Business Combinations. This statement
establishes principles and requirements for how an acquirer recognizes and measures in its
financial statements the identifiable assets acquired, the liabilities assumed, the goodwill
acquired, and any noncontrolling interest in the acquiree. In addition, SFAS 141(R) establishes
disclosure requirements to enable the evaluation of the nature and financial effects of the
business combination. SFAS 141(R) applies prospectively to business combinations for which the
acquisition date is during fiscal years beginning on or after December 15, 2008, the effective date
of this statement. We will adopt SFAS 141(R) in the first quarter of our fiscal year 2010 beginning
July 1, 2009.
2. Inventories
Inventories are stated at the lower of cost or market, with cost determined on a first-in,
first-out basis.
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
June 30, |
|
|
|
2007 |
|
|
2007 |
|
Materials |
|
$ |
22,606 |
|
|
$ |
20,189 |
|
Work in process |
|
|
11,737 |
|
|
|
11,253 |
|
Finished goods |
|
|
28,006 |
|
|
|
28,013 |
|
|
|
|
|
|
|
|
|
|
$ |
62,349 |
|
|
$ |
59,455 |
|
|
|
|
|
|
|
|
3. Stockholders Equity
Changes in the components of stockholders equity for the six months ended December 31, 2007 were
as follows:
|
|
|
|
|
Net earnings |
|
$ |
18,881 |
|
Foreign currency translation gain |
|
|
3,602 |
|
Common stock and additional paid-in capital effects of
stock option activity |
|
|
1,203 |
|
Cash dividends declared on common stock |
|
|
(16,988 |
) |
Benefit plan adjustments |
|
|
144 |
|
Unrealized gain on available-for-sale securities |
|
|
372 |
|
Cumulative effect of FIN 48 adoption |
|
|
(2,815 |
) |
|
|
|
|
Total increase in stockholders equity |
|
$ |
4,399 |
|
|
|
|
|
6
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
4. Earnings Per Share
The computation of basic and diluted earnings per share for the three and six months ended December
31, 2007 and 2006 is shown below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
Three Months Ended |
|
|
|
12/31/07 |
|
|
12/31/06 |
|
|
12/31/07 |
|
|
12/31/06 |
|
Net earnings |
|
$ |
18,881 |
|
|
$ |
7,868 |
|
|
$ |
7,089 |
|
|
$ |
3,335 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding
for basic earnings per share |
|
|
15,350 |
|
|
|
15,213 |
|
|
|
15,354 |
|
|
|
15,205 |
|
Effect of dilutive employee stock awards |
|
|
146 |
|
|
|
259 |
|
|
|
161 |
|
|
|
283 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding
for diluted earnings per share |
|
|
15,496 |
|
|
|
15,472 |
|
|
|
15,515 |
|
|
|
15,488 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share |
|
$ |
1.23 |
|
|
$ |
0.52 |
|
|
$ |
0.46 |
|
|
$ |
0.22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
$ |
1.22 |
|
|
$ |
0.51 |
|
|
$ |
0.46 |
|
|
$ |
0.22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common shares related to options outstanding under our stock option plans amounting to 677 thousand
and 826 thousand shares for the six months ended December 31, 2007 and 2006, respectively, were
excluded from the computation of diluted earnings per share as the effect would have been
antidilutive. For the three months ended December 31, 2007 and 2006, 556 thousand and 829 thousand
shares, respectively, were excluded from the calculation for the same reason.
5. Comprehensive Income
Comprehensive income for the three and six months ended December 31, 2007 and 2006 is shown below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
Three Months Ended |
|
|
|
12/31/07 |
|
|
12/31/06 |
|
|
12/31/07 |
|
|
12/31/06 |
|
Net earnings |
|
$ |
18,881 |
|
|
$ |
7,868 |
|
|
$ |
7,089 |
|
|
$ |
3,335 |
|
Foreign currency translation gain |
|
|
3,602 |
|
|
|
968 |
|
|
|
688 |
|
|
|
1,153 |
|
Benefit plan adjustments |
|
|
144 |
|
|
|
|
|
|
|
43 |
|
|
|
|
|
Unrealized gain (loss) on available-for-sale
securities, net of tax |
|
|
372 |
|
|
|
227 |
|
|
|
204 |
|
|
|
(39 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income |
|
$ |
22,999 |
|
|
$ |
9,063 |
|
|
$ |
8,024 |
|
|
$ |
4,449 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
6. Segment Information
We develop, manufacture and sell medical devices in two reportable segments, Cardiac Assist /
Monitoring Products and Interventional / Vascular Products.
The Cardiac Assist / Monitoring Products segment includes electronic intra-aortic balloon pumps and
catheters that are used in the treatment of cardiovascular disease, endoscopic vessel harvesting
products that provide a less-invasive alternative to surgical harvesting of blood vessels for use
in coronary bypass, manual compression assist devices used to stop bleeding following femoral
arterial catheterization in diagnostic and interventional procedures, and electronic physiological
monitors and central monitoring systems that provide for patient safety and management of patient
care.
The Interventional / Vascular Products segment includes vascular closure devices, which are used to
seal arterial puncture wounds after cardiovascular catheterization procedures, interventional
radiology products used in dialysis access, and a proprietary line of knitted and woven polyester
vascular grafts, patches and graft stents for reconstructive vascular and cardiovascular surgery.
We have aggregated our product lines into two reportable segments based on similar manufacturing
processes, economic characteristics, distribution channels, regulatory environments, and customers.
Management evaluates the revenue and profitability performance of each of our product lines to make
operating and strategic decisions. We have no intersegment revenue.
8
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
6. Segment Information (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cardiac |
|
|
|
|
|
|
|
|
|
|
|
|
Assist / |
|
|
Interventional / |
|
|
Corporate |
|
|
|
|
|
|
Monitoring |
|
|
Vascular |
|
|
and |
|
|
|
|
|
|
Products |
|
|
Products |
|
|
Other |
|
|
Consolidated |
|
Six months ended December 31, 2007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales to external customers |
|
$ |
170,201 |
|
|
$ |
19,869 |
|
|
$ |
630 |
|
|
$ |
190,700 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating earnings (loss) |
|
$ |
17,608 |
|
|
$ |
(1,151 |
) |
|
$ |
(161 |
) |
|
$ |
16,296 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended December 31, 2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales to external customers |
|
$ |
161,725 |
|
|
$ |
20,498 |
|
|
$ |
577 |
|
|
$ |
182,800 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating earnings (loss) |
|
$ |
18,528 |
|
|
$ |
(9,808 |
) |
|
$ |
(767 |
) |
|
$ |
7,953 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended December 31, 2007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales to external customers |
|
$ |
92,419 |
|
|
$ |
10,664 |
|
|
$ |
317 |
|
|
$ |
103,400 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating earnings |
|
$ |
11,660 |
|
|
$ |
(1,085 |
) |
|
$ |
38 |
|
|
$ |
10,613 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended December 31, 2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales to external customers |
|
$ |
85,265 |
|
|
$ |
10,087 |
|
|
$ |
248 |
|
|
$ |
95,600 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating earnings (loss) |
|
$ |
9,124 |
|
|
$ |
(7,027 |
) |
|
$ |
(284 |
) |
|
$ |
1,813 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
Three Months Ended |
|
|
|
12/31/07 |
|
|
12/31/06 |
|
|
12/31/07 |
|
|
12/31/06 |
|
Reconciliation to consolidated
earnings before income taxes: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated operating earnings |
|
$ |
16,296 |
|
|
$ |
7,953 |
|
|
$ |
10,613 |
|
|
$ |
1,813 |
|
Interest income, net |
|
|
1,016 |
|
|
|
1,276 |
|
|
|
475 |
|
|
|
577 |
|
Dividend income |
|
|
|
|
|
|
196 |
|
|
|
|
|
|
|
196 |
|
Gain on sale of investment |
|
|
13,173 |
|
|
|
1,273 |
|
|
|
|
|
|
|
1,273 |
|
Other, net |
|
|
(251 |
) |
|
|
(224 |
) |
|
|
(182 |
) |
|
|
(131 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated earnings before
income taxes |
|
$ |
30,234 |
|
|
$ |
10,474 |
|
|
$ |
10,906 |
|
|
$ |
3,728 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beginning fiscal 2008, net sales of Safeguard and the products associated operating loss are now
included within the Cardiac Assist / Monitoring Products segment (formerly reported in the
Interventional / Vascular Products segment). Net sales and operating earnings for the three and six
months ended December 31, 2006 for both segments have been adjusted to reflect this change.
Operating earnings within Cardiac Assist / Monitoring Products for the three and six months ended
December 31, 2006 includes special charges of $2.0 million related to the workforce reductions in
the Patient Monitoring Division and the European sales organization.
Operating loss within Interventional / Vascular Products for the three and six months ended
December 31, 2006 includes special charges of $5.3 million related to the plan to exit the vascular
closure market and phase out the Interventional Products business and the workforce reductions in
the European sales organization.
Net sales of life science products are included within Corporate and Other. Segment SG&A expenses
include allocated corporate G&A charges.
9
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
7. Stock-Based Awards
We maintain the following equity incentive plans: the 2005 Equity Incentive Plan, the Amended and
Restated 1995 Employee Stock Option Plan, the Amended and Restated Non-Employee Director Plan, and
option agreements with certain consultants.
The 2005 Equity Incentive Plan (2005 Plan), approved by the stockholders in December 2005,
authorized 1,200,000 shares covering several different types of awards, including stock options,
performance shares, performance units, stock appreciation rights, restricted shares, and deferred
shares.
The stock option plans provide that options may be granted at an exercise price of 100% of fair
market value of our common stock on the date of grant, may be exercised in full or in installments,
at the discretion of the Board of Directors, and must be exercised within ten years from the date
of grant. We recognize stock-based compensation expense on a straight-line basis over the vesting
period, generally four years.
In accordance with SFAS No. 123(R), Share-Based Payment, we recorded stock-based compensation
expense for the cost of stock options and restricted stock (together, stock-based awards).
Stock-based compensation expense for the three and six months ended December 31, 2007 and 2006 was
recorded in the condensed consolidated statements of earnings as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
Three Months Ended |
|
|
|
12/31/07 |
|
|
12/31/06 |
|
|
12/31/07 |
|
|
12/31/06 |
|
Cost of sales |
|
$ |
22 |
|
|
$ |
13 |
|
|
$ |
14 |
|
|
$ |
6 |
|
Research and development expenses |
|
|
105 |
|
|
|
69 |
|
|
|
49 |
|
|
|
35 |
|
Selling, general and administrative expenses |
|
|
430 |
|
|
|
278 |
|
|
|
184 |
|
|
|
178 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation expense |
|
$ |
557 |
|
|
$ |
360 |
|
|
$ |
247 |
|
|
$ |
219 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation expense, net
of tax |
|
$ |
329 |
|
|
$ |
213 |
|
|
$ |
145 |
|
|
$ |
130 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
7. Stock-Based Awards (Continued)
The fair value of the stock options granted was estimated on the date of grant using a
Black-Scholes option valuation model that uses the assumptions noted in the following table. The
expected dividend yield is based on the annualized projection of regular and special dividends.
Expected volatility is based on historical volatility for a period equal to the stock options
expected life and calculated on a monthly basis. The risk-free rate is based on the U.S. Treasury
yield curve in effect at the time of grant. The expected life (estimated period of time
outstanding) of stock options granted was estimated using the historical exercise behavior of
employees for grants with a 10-year term.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
Three Months Ended |
|
|
December 31, |
|
December 31, |
|
|
2007 |
|
2006 |
|
2007 |
|
2006 |
Expected dividend yield |
|
|
* |
|
|
|
4.04 |
% |
|
|
* |
|
|
|
4.04 |
% |
Expected volatility |
|
|
* |
|
|
|
28 |
% |
|
|
* |
|
|
|
27 |
% |
Risk-free interest rate |
|
|
* |
|
|
|
4.58 |
% |
|
|
* |
|
|
|
4.62 |
% |
Expected life (in years) |
|
|
* |
|
|
|
4.8 |
|
|
|
* |
|
|
|
4.8 |
|
There were no stock options granted during the three and six months ended December 31, 2007.
SFAS 123(R) requires that cash flows resulting from tax benefits attributable to tax deductions in
excess of the stock-based compensation expense recognized for those options (excess tax benefits)
be classified as financing cash flows. As a result, we classified $61 thousand and $93 thousand of
excess tax benefits as financing cash flows for the six months ended December 31, 2007 and 2006,
respectively.
Stock Options
We have an employee stock compensation plan, the Amended and Restated 1995 Employee Stock Option
Plan, covering 4,150,000 shares of common stock, a non-employee director plan for members of the
Board of Directors covering 150,000 shares of common stock, and option agreements with certain
consultants. Stock options have generally been granted with a 4-year vesting period and 10-year
term. The stock options vest in equal annual installments over the vesting period. Under the
provisions of SFAS 123(R), members of the Board of Directors are considered employees.
11
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
7. Stock-Based Awards (Continued)
Stock Options (Continued)
Changes in our stock options for the six months ended December 31, 2007 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
Number of |
|
Average |
|
|
Options |
|
Exercise Price |
Options outstanding, beginning of year |
|
|
1,741,161 |
|
|
$ |
32.47 |
|
Granted |
|
|
|
|
|
|
|
|
Exercised |
|
|
(20,837 |
) |
|
|
29.56 |
|
Forfeited/Expired |
|
|
(63,050 |
) |
|
|
35.14 |
|
|
|
|
|
|
|
|
|
|
Options outstanding, end of period |
|
|
1,657,274 |
|
|
|
32.40 |
|
|
|
|
|
|
|
|
|
|
Options vested and expected to vest, end of period |
|
|
1,631,109 |
|
|
|
32.36 |
|
|
|
|
|
|
|
|
|
|
Options exercisable, end of period |
|
|
1,514,862 |
|
|
|
32.16 |
|
|
|
|
|
|
|
|
|
|
At December 31, 2007, there were 2,359,927 shares of common stock reserved for stock options. We
generally issue shares for the exercise of stock options from unissued reserved shares. We
anticipate that shares repurchased will offset shares to be issued for the stock-based awards and
reduce the dilutive impact of share-based activity. However, since the timing and amount of future
repurchases is not known, we cannot estimate the number of shares expected to be repurchased during
the remainder of fiscal 2008.
The weighted average remaining contractual term was approximately 5.0 years for stock options
outstanding and approximately 4.6 years for stock options exercisable as of December 31, 2007. The
weighted average fair value of options granted during the three and six months ended December 31,
2006 was $6.84 and $6.81 per share, respectively. There were no stock options issued during the
three and six months ended December 31, 2007.
The total intrinsic value (the excess of the market price over the exercise price) was
approximately $7.5 million for stock options outstanding and $7.3 million for stock options
exercisable as of December 31, 2007. The total intrinsic value for stock options exercised during
the three and six months ended December 31, 2007 was approximately $155 thousand and $164 thousand,
respectively. The total intrinsic value for stock options exercised during the three and six months
ended December 31, 2006 was approximately $210 thousand and $303 thousand, respectively.
The amount of cash received from the exercise of stock options was approximately $448 thousand and
the related tax benefit was approximately $30 thousand for the six months ended December 31, 2007.
As of December 31, 2007, unrecognized stock-based compensation expense related to stock options was
approximately $1.3 million and is expected to be recognized over a weighted average period of 2.6
years.
12
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
7. Stock-Based Awards (Continued)
Restricted Stock
The following table summarizes restricted stock activity under the 2005 Plan for the six months
ended December 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
Average |
|
|
Shares |
|
Grant Price |
Nonvested, beginning of year |
|
|
3,908 |
|
|
$ |
35.84 |
|
Granted |
|
|
65,920 |
|
|
|
32.60 |
|
Vested |
|
|
|
|
|
|
|
|
Forfeited |
|
|
(6,660 |
) |
|
|
32.44 |
|
|
|
|
|
|
|
|
|
|
Nonvested, end of period |
|
|
63,168 |
|
|
|
32.82 |
|
|
|
|
|
|
|
|
|
|
As of December 31, 2007, unrecognized stock-based compensation expense related to nonvested awards
was approximately $1.6 million and is expected to be recognized over a weighted average period of
3.7 years.
8. Retirement Benefit Plans
Defined Benefit Pension Plans U.S. and International
We have a defined benefit pension plan designed to provide retirement benefits to eligible U.S.
employees. U.S. pension benefits are based on years of service, compensation, and the primary
social security benefits. Funding for the U.S. plan is within the range prescribed under the
Employee Retirement Income Security Act of 1974. Retirement benefits under the International plan
are based on years of service, final average earnings, and social security benefits. Funding
policies for the International plan are based on local statutes and the assets are invested in
guaranteed insurance contracts.
Supplemental Executive Retirement Plans (SERP)
We have noncontributory, unfunded supplemental defined benefit retirement plans (SERP) for the
Chairman and Chief Executive Officer, Mr. Lawrence Saper, and certain former key officers. Life
insurance has been purchased to recover a portion of the net after tax cost for these SERPs. The
assumptions used to develop the supplemental pension cost and the actuarial present value of the
projected benefit obligation are reviewed annually.
Post-Retirement Medical Benefits Plan
In addition to the SERP, we have a noncontributory, unfunded post-retirement medical plan for Mr.
Saper. The post-retirement medical plan provides certain lifetime medical benefits to Mr. Saper and
his wife upon the termination of Mr. Sapers employment with us.
13
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
8. Retirement Benefit Plans (Continued)
Net Periodic Benefit Costs
The components of net periodic benefit costs of our U.S. and International defined benefit pension
plans, the SERP, and the post-retirement medical benefits plan include the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended December 31, |
|
|
|
2007 |
|
|
2006 |
|
|
2007 |
|
|
2006 |
|
|
|
U.S. and International |
|
|
SERP |
|
Service cost |
|
$ |
1,451 |
|
|
$ |
1,256 |
|
|
$ |
188 |
|
|
$ |
175 |
|
Interest cost |
|
|
2,225 |
|
|
|
1,893 |
|
|
|
528 |
|
|
|
500 |
|
Expected return on assets |
|
|
(2,122 |
) |
|
|
(1,720 |
) |
|
|
|
|
|
|
|
|
Amortization of: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
209 |
|
|
|
242 |
|
|
|
6 |
|
|
|
4 |
|
Unrecognized prior service (credit) cost |
|
|
(20 |
) |
|
|
6 |
|
|
|
(48 |
) |
|
|
(37 |
) |
Curtailment loss |
|
|
|
|
|
|
14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit costs |
|
$ |
1,743 |
|
|
$ |
1,691 |
|
|
$ |
674 |
|
|
$ |
642 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employer contributions |
|
$ |
2,500 |
|
|
$ |
1,100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
December 31, |
|
|
|
2007 |
|
|
2006 |
|
|
|
Post-Retirement Medical |
|
Service cost |
|
$ |
|
|
|
$ |
|
|
Interest cost |
|
|
8 |
|
|
|
6 |
|
Expected return on assets |
|
|
|
|
|
|
|
|
Amortization of: |
|
|
|
|
|
|
|
|
Net loss |
|
|
1 |
|
|
|
1 |
|
Unrecognized prior service cost |
|
|
2 |
|
|
|
2 |
|
|
|
|
|
|
|
|
Net periodic benefit costs |
|
$ |
11 |
|
|
$ |
9 |
|
|
|
|
|
|
|
|
14
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
8. Retirement Benefit Plans (Continued)
Net Periodic Benefit Costs (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31, |
|
|
|
2007 |
|
|
2006 |
|
|
2007 |
|
|
2006 |
|
|
|
U.S. and International |
|
|
SERP |
|
Service cost |
|
$ |
726 |
|
|
$ |
560 |
|
|
$ |
94 |
|
|
$ |
87 |
|
Interest cost |
|
|
1,112 |
|
|
|
844 |
|
|
|
264 |
|
|
|
250 |
|
Expected return on assets |
|
|
(1,061 |
) |
|
|
(767 |
) |
|
|
|
|
|
|
|
|
Amortization of: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
105 |
|
|
|
108 |
|
|
|
3 |
|
|
|
2 |
|
Unrecognized prior service (credit) cost |
|
|
(10 |
) |
|
|
3 |
|
|
|
(24 |
) |
|
|
(18 |
) |
Curtailment loss |
|
|
|
|
|
|
14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit costs |
|
$ |
872 |
|
|
$ |
762 |
|
|
$ |
337 |
|
|
$ |
321 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employer contributions |
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
December 31, |
|
|
|
2007 |
|
|
2006 |
|
|
|
Post-Retirement Medical |
|
Service cost |
|
$ |
|
|
|
$ |
|
|
Interest cost |
|
|
4 |
|
|
|
3 |
|
Expected return on assets |
|
|
|
|
|
|
|
|
Amortization of: |
|
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
1 |
|
Unrecognized prior service cost |
|
|
1 |
|
|
|
1 |
|
|
|
|
|
|
|
|
Net periodic benefit costs |
|
$ |
5 |
|
|
$ |
5 |
|
|
|
|
|
|
|
|
15
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
9. Intangible Assets
The following is a summary of our intangible assets:
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
June 30, |
|
|
|
2007 |
|
|
2007 |
|
Amortized intangible assets: |
|
|
|
|
|
|
|
|
Purchased technology |
|
$ |
22,370 |
|
|
$ |
22,176 |
|
Licenses |
|
|
5,651 |
|
|
|
5,272 |
|
Customer relationships and other |
|
|
1,140 |
|
|
|
1,077 |
|
|
|
|
|
|
|
|
Subtotal |
|
|
29,161 |
|
|
|
28,525 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated amortization: |
|
|
|
|
|
|
|
|
Purchased technology |
|
|
(1,653 |
) |
|
|
(1,300 |
) |
Licenses |
|
|
(2,142 |
) |
|
|
(1,512 |
) |
Customer relationships and other |
|
|
(79 |
) |
|
|
(12 |
) |
|
|
|
|
|
|
|
Subtotal |
|
|
(3,874 |
) |
|
|
(2,824 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized intangible assets, net |
|
$ |
25,287 |
|
|
$ |
25,701 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Indefinite-lived intangible assets: |
|
|
|
|
|
|
|
|
Trade name |
|
$ |
394 |
|
|
$ |
373 |
|
|
|
|
|
|
|
|
The components of intangible assets represent the acquisition date fair value of intangible assets
acquired from Artema Medical, purchased technology for the ClearGlide® endoscopic vessel harvesting
device, a license for the manufacture of our Anestar® anesthesia delivery systems, purchased
technology for the X-Site® suture-based vascular closure device, and purchased technology for the
ProLumen thrombectomy device.
Amortization expense was approximately $1.1 million and $0.5 million for the six months ended
December 31, 2007 and 2006, respectively, and $0.5 million and $0.3 million for the three months
ended December 31, 2007 and 2006, respectively.
Expected future amortization expense for intangible assets subject to amortization for the
remainder of fiscal 2008 and the full fiscal years 2009 through 2012 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ending June 30, |
|
|
2008 |
|
2009 |
|
2010 |
|
2011 |
|
2012 |
Amortization expense |
|
$ |
957 |
|
|
$ |
1,913 |
|
|
$ |
2,014 |
|
|
$ |
1,538 |
|
|
$ |
1,628 |
|
The remaining weighted average amortization period for intangible assets is approximately 10 years.
16
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
10. Goodwill
The following is a summary of the changes in the carrying amount of goodwill for the six months
ended December 31, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cardiac |
|
|
|
|
|
|
|
|
|
Assist / |
|
|
Interventional / |
|
|
|
|
|
|
Monitoring |
|
|
Vascular |
|
|
|
|
|
|
Products |
|
|
Products |
|
|
Consolidated |
|
Goodwill, beginning of year |
|
$ |
11,079 |
|
|
$ |
1,781 |
|
|
$ |
12,860 |
|
Adjustment to acquisition purchase price |
|
|
9 |
|
|
|
|
|
|
|
9 |
|
Currency adjustment |
|
|
726 |
|
|
|
|
|
|
|
726 |
|
|
|
|
|
|
|
|
|
|
|
Goodwill, end of period |
|
$ |
11,814 |
|
|
$ |
1,781 |
|
|
$ |
13,595 |
|
|
|
|
|
|
|
|
|
|
|
11. Commitments and Contingencies
Legal Proceedings
We are subject to certain legal actions, including product liability matters, arising in the
ordinary course of our business. We believe we have meritorious defenses in all material pending
lawsuits. We also believe that we maintain adequate insurance against any potential liability for
product liability litigation. In accordance with U.S. GAAP, we accrue for legal matters if it is
probable that a liability has been incurred and an amount is reasonably estimable.
As noted in our Form 10-K for the fiscal year ended June 30, 2007, on March 18, 2005, Johns Hopkins
University and Arrow International, Inc. filed a complaint in the United States District Court for
the District of Maryland, seeking a permanent injunction and damages for patent infringement. They
allege that our ProLumen Rotational Thrombectomy System infringes the claims of their U.S. patents
5,766,191 and 6,824,551. We have filed an answer denying such infringement and discovery has been
completed. On October 13, 2006, Johns Hopkins and Arrow filed a second complaint based upon their
newly issued U.S. patent 7,108,704 claiming our ProLumen device infringes the claims of this
patent. The parties had agreed that this matter should be consolidated with the first case and the
consolidation has taken place. A jury trial took place in late
June 2007 resulting in a finding
that the ProLumen product infringed the three patents, a finding that we owed a $690 thousand royalty to the
plaintiffs, and the issuance of an injunction precluding us from
further selling the ProLumen product. We filed a Notice of Appeal
regarding the lower courts decision and subsequently filed an
Appellate Brief on October 12, 2007. The appellees filed a
Response Brief in November 2007. We believe we will be successful on appeal in overturning the lower courts
findings and, therefore, an accrual for the royalty liability has not been recorded and no
impairment of the assets related to ProLumen has been taken.
On December 6, 2007, The General Hospital Corporation and Welch Allyn Protocol, Inc.
filed an action for patent infringement against the Company in the United States District
Court for the District of Massachusetts. In their complaint, the Plaintiffs allege that the
Company has infringed and is infringing upon U.S. Patent No.
5,319,363 ( 363
Patent). The Plaintiffs further allege in their complaint that the infringing products
include products and accessories marketed and/or sold by the Company under its
Panorama, Passport, Passport 2 and Spectrum trade names and also alleges that other
products and accessories of the Company may also infringe the 363 Patent. The
complaint demands, among other things, a preliminary and permanent injunction against
the Company, damages and attorneys fees. While the complaint has not yet been formally
served upon the Company, the Company believes that it has meritorious
defenses to any
such claims and intends to defend this action vigorously.
17
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
11. Commitments and Contingencies (Continued)
Credit Arrangements
We had available unsecured lines of credit at December 31, 2007 totaling $99.5 million, with
interest payable at LIBOR-based rates determined by the borrowing period. At December 31, 2007, we
had no outstanding borrowings. Of the total available, $49.0 million expires in March 2008 and
$25.0 million expires in October 2008. These lines of credit are renewable annually at the option
of the banks, and we plan to seek renewal. We also have $25.5 million in credit lines with no
expiration date. We have approximately $1.0 million in letters of credit outstanding as security
for inventory purchases from an overseas vendor.
12. Dividends and Stock Repurchase Program
In September 2007, the Board of Directors declared a regular quarterly cash dividend of $0.10 per
share and a special dividend of $1.00 per share, both paid on October 15, 2007 to stockholders of
record as of October 1, 2007. In December 2006, the Board of Directors increased the regular
quarterly dividend for the second quarter of fiscal 2007 to $0.10 per share from $0.07 per share,
paid on January 16, 2007 to stockholders of record as of December 27, 2006. In September 2006, the
Board of Directors declared a regular quarterly cash dividend of $0.07 per share and a special
dividend of $1.00 per share, both paid on October 6, 2006 to stockholders of record as of September
28, 2006.
In addition, during the first quarter of fiscal 2007, the Board of Directors approved a stock
repurchase program for $40 million of our common stock. Purchases under this program may be made
from time to time on the open market and in privately negotiated transactions, and may be
discontinued at any time at our discretion. During the six months ended December 31, 2007, we did
not repurchase any of our shares. During the six months ended December 31, 2006, we purchased
approximately 56 thousand shares at a cost of $1.7 million.
13. Income Taxes
In the second quarter and first six months of fiscal 2008, the consolidated effective tax rate was
35.0% and 37.6%, respectively, compared to 10.5% and 24.9% in the second quarter and first six
months last year, respectively. The higher tax rates in the fiscal 2008 periods were primarily
attributable to the higher tax rate on the gain on sale of investment in the first quarter of
fiscal 2008, expiration of the extraterritorial income exclusion on December 31, 2006, and a shift
in the geographical mix of earnings to higher taxed jurisdictions. The lower tax rates in the
fiscal 2007 periods were primarily attributable to the higher tax benefit on the $7.3 million
second quarter fiscal 2007 special charges and the utilization of a foreign tax loss carryforward
(that had a valuation allowance) on the $1.3 million gain on sale of an investment. Additionally,
the second quarter and first six months of fiscal 2007 benefited from retroactive recognition of
the U.S. Research Credit.
18
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
13. Income Taxes (Continued)
Adoption of New Accounting Standard
On July 1, 2007, we adopted the provisions of FIN 48. The impact of adopting FIN 48 on our
condensed consolidated balance sheet is summarized below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at |
|
|
|
|
|
Balance at |
|
|
June 30, |
|
FIN 48 |
|
July 1, |
|
|
2007 |
|
Adjustment |
|
2007 |
Other assets |
|
$ |
34,897 |
|
|
$ |
239 |
|
|
$ |
35,136 |
|
Accrued expenses / income taxes payable |
|
|
17,661 |
|
|
|
(1,578 |
) |
|
|
16,083 |
|
Other liabilities |
|
|
25,220 |
|
|
|
4,632 |
|
|
|
29,852 |
|
Retained earnings |
|
|
294,765 |
|
|
|
(2,815 |
) |
|
|
291,950 |
|
The total amount of unrecognized tax benefits as of July 1, 2007 was $8.5 million, of which $4.7
million would impact our effective tax rate if recognized. We anticipate that approximately $1.6
million of the unrecognized tax benefits will be recognized in the next 12 months, primarily due to
the expiration of statutes of limitations. Such recognition may impact our effective tax rate.
We recognize interest and penalties related to income tax matters in income tax expense. We had
approximately $0.8 million accrued for interest and penalties as of July 1, 2007.
We operate within multiple taxing jurisdictions and are subject to routine corporate income tax
audits in many of those jurisdictions. These audits can involve complex issues, including
challenges regarding the timing and amount of deductions and credits and the allocation of income
among various tax jurisdictions. Our U.S. income tax returns for fiscal 1998 and prior years have
been audited by the Internal Revenue Service and are closed. The U.S. statutory period has expired
for fiscal years through 2003, and is open for subsequent periods. The State of New Jersey is
currently examining our tax returns for fiscal 2002 through 2006. For the remaining states, our
fiscal 2003 through 2007 tax returns remain open for examination by the tax authorities under a
general four year statute of limitations. Our foreign tax returns generally remain open for
examination from fiscal 2004 through 2007 under a general three year statute of limitations.
19
Datascope Corp. and Subsidiaries
Notes to Condensed Consolidated Financial Statements Continued
(Unaudited, in thousands except per share data)
14. Special Items
In fiscal 2007, we recorded special items totaling $12.8 million. These items consisted of the
following:
|
|
|
Interventional Products Division exit plan totaling $5.0 million. |
|
|
|
|
Severance, settlement, and other termination benefits of $6.0 million for workforce
reductions in the Patient Monitoring Division, the European sales organization, Corporate,
and Genisphere. |
|
|
|
|
Goodwill impairment charge of $2.3 million related to Genisphere. |
|
|
|
|
Inquiry expenses of $1.7 million related to the Audit Committee investigations of ethics
line reports. |
|
|
|
|
Gain on sale of ProGuide assets totaling $2.2 million. |
During the first six months of fiscal 2008, severance and settlement payments of $3.1 million and
inquiry expenses of $0.1 million were paid reducing the remaining liability of $3.5 million at June
30, 2007 to $0.3 million at December 31, 2007. The remaining liability is included in accrued
compensation in our condensed consolidated balance sheet and is expected to be fully utilized by
the end of fiscal 2008.
15. Gain on Sale of Investment
We had a preferred stock investment of $5.0 million in Masimo Corporation, a supplier to our
Patient Monitoring business. On August 13, 2007, Masimo completed its initial public offering, and
concurrently, we sold substantially all of our investment in Masimo, resulting in a pretax gain on
the sale of approximately $13.2 million.
16. Subsequent Event
On January 9, 2008, the Board of Directors declared a regular quarterly cash dividend of $0.10 per
share, paid on February 8, 2008 to stockholders of record as of January 22, 2008.
20
Datascope Corp. and Subsidiaries
|
|
|
Item 2. |
|
Managements Discussion and Analysis of Financial Condition and
Results of Operations |
Business Overview
Datascope Corp. is a diversified medical device company that develops, manufactures and markets
proprietary products for clinical health care markets in interventional cardiology and
radiology, cardiovascular and vascular surgery, anesthesiology, emergency medicine and critical
care. We have four product lines that are aggregated into two reportable segments, Cardiac
Assist / Monitoring Products and Interventional / Vascular Products. We have aggregated our
product lines into two segments based on similar manufacturing processes, economic
characteristics, distribution channels, regulatory environments and customers. Management
evaluates the revenue and profitability performance of each of our product lines to make
operating and strategic decisions. The Cardiac Assist / Monitoring Products segment accounted
for 87% of total sales in fiscal 2007 and 89% in the first six months of fiscal 2008. Our
products are sold worldwide by direct sales representatives and independent distributors. Our
largest geographic markets are the United States, Europe and Japan.
We believe that customers, primarily hospitals and other medical institutions, choose among
competing products on the basis of product performance, features, price and service. In general,
we believe price has become an important factor in hospital purchasing decisions because of
pressure to cut costs. These pressures on hospitals result from Federal and state regulations
that limit reimbursement for services provided to Medicare and Medicaid patients. There are also
cost containment pressures on healthcare systems outside the United States, particularly in
certain European countries. Many companies, some of which are substantially larger than us, are
engaged in manufacturing competing products. Our products are generally not affected by economic
cycles.
Our sales growth depends in part upon the successful development and marketing of new products.
We continue to invest in research and development. Our growth strategy includes selective
acquisitions or licensing of products and technologies from other companies.
In October 2007, we announced the launch of NetGuard, our new, revolutionary wireless clinician
alert system. NetGuard creates a new paradigm in patient monitoring because it is the first
monitoring system that is specifically designed to protect todays unmonitored patient by
detecting life-threatening heart rhythms. We estimate that tens of thousands of patients die
each year from cardiac arrest precipitated by a dangerous heart rhythm that is unrelated to the
patients illness.
Our initial focus is to create selected beta site installations and then launch our national
sales campaign for NetGuard. The beta sites are expected to turn into reference sites
for NetGuard. Reference sites will be instrumental in promoting acceptance and sales of NetGuard
in the broader market by physicians and hospitals around the world
In December 2007, we booked the first order for NetGuard. In this installation, NetGuard will
provide for continuous ECG monitoring of 50 patients in the Emergency Department of a 300-bed
hospital in the Southwest region of the United States. In support of the NetGuard concept, the
patients that will be continuously monitored by NetGuard are currently unmonitored. Installation
is planned for the fourth quarter of fiscal 2008.
21
In October 2007, we formed a new subsidiary, Datascope Japan K.K., to manage our Intra-Aortic
Balloon Pump (IABP) business in Japan since Edwards Lifesciences Ltd., our former distributor,
planned to exit that business in Japan at the end of December 2007. Datascope Japan K.K. was
formed to expand our overall business in Japan and will be responsible for import, product
service, sales support and product surveillance of the IABP business. USCI Holdings Ltd., one of
the premier medical device distribution organizations in Japan, will be responsible for sales
distribution throughout Japan. USCI will give us comprehensive sales coverage throughout Japan.
In June 2007, we acquired Artema Medical AB, a privately held Swedish manufacturer of
proprietary gas analyzers, which identify and measure the concentration of anesthetic agents
used during surgery. The acquisition of Artema expands our product offerings targeted toward the
surgical marketplace. Artema is the developer of a compact and power efficient side-stream gas
analyzer, the Artema AION, which is sold on an OEM-basis to patient monitoring companies. We
intend to maintain Artema as a stand-alone company serving its OEM customers and to incorporate
Artemas gas bench technology in our patient monitors for use in ORs, significantly reducing the
cost while enhancing the capabilities of those monitors. The global market for anesthetic
measurement equipment is estimated at $80 million annually.
In January 2007, we purchased a five-year license from the Sorin Group of Milan, Italy, for
exclusive worldwide distribution rights to Sorins peripheral vascular stent products, excluding
the United States and Japan. As part of that agreement, we received an option to purchase
Sorins worldwide peripheral vascular stent business within two years of the agreement date. We
estimate the worldwide market for peripheral vascular stents and percutaneous transluminal
angioplasty balloons, excluding the United States and Japan, to be $190 million annually.
In January 2006, we acquired the ClearGlide® endoscopic vessel harvesting (EVH)
product from Ethicon, a Johnson & Johnson company. EVH devices enable less-invasive techniques for the
harvesting of suitable vessels for use in coronary artery bypass grafting. The vessel harvesting
product line was integrated into the Cardiac Assist business, which markets its products to
cardiac surgeons who perform coronary bypass graft surgery. We estimate the potential annual
market for EVH to be $220 million.
In October 2006, we announced a plan to exit the vascular closure market and phase out the
Interventional Products (IP) business. We have engaged an investment bank as financial advisor
for the sale of our vascular closure devices, VasoSeal®, On-Site and X-Site®. We plan to seek
the sale or independent distribution of our ProLumen thrombectomy device for the interventional
radiology market; although these plans are subject to the reversal of a verdict that is being
appealed (see Legal Proceedings below for a discussion of litigation related to ProLumen). In
February 2007, we completed the sale of our ProGuide chronic dialysis catheter and the
associated assets for $3.0 million plus a royalty on future sales of the ProGuide catheter.
Our Safeguard assisted pressure device received FDA 510(k) clearance to claim reduced manual
compression time to stop bleeding following femoral arterial catheterization in diagnostic and
interventional procedures in March 2007. In May 2007 we tripled the Safeguard sales
and marketing effort in the United States from a
pilot sales group to the entire Cardiac Assist direct sales force. Safeguard is aimed at an
estimated $125 million annual worldwide market.
22
We are committed to improving our operating margins through increasing the efficiency of our
manufacturing operations and cost containment programs.
Our financial position continued strong at the end of December 2007. Cash and marketable
investments were $56.8 million compared to $47.5 million at June 30, 2007. On January 9, 2008,
the Board of Directors declared a regular quarterly cash dividend of $0.10 per share payable on
February 8, 2008 to stockholders of record as of January 22, 2008.
Results of Operations
Net Sales
Net sales increased 8% to $103.4 million in the second quarter and 4% to $190.7 million in the
first six months of fiscal 2008 compared to the corresponding periods last year. Favorable foreign
exchange translation, as a result of the weaker United States dollar relative to the Euro and the
British Pound, increased sales by $2.1 million in the second quarter and $3.3 million in the first
six months of fiscal 2008.
Sales in the United States were $53.5 million and $102.0 million in the second quarter and first
six months of fiscal 2008, respectively, compared to $57.3 million and $111.2 million,
respectively, for the corresponding periods last year with the decrease primarily attributable to
lower sales in the Patient Monitoring and Interventional Products businesses.
Sales in international markets increased 30% to $49.9 million in the second quarter and 24% to
$88.7 million in the first six months of fiscal 2008 compared to the corresponding periods last
year, due to increases in all businesses except Interventional Products and favorable foreign
exchange translation as noted above.
Sales of the Cardiac Assist / Monitoring Products segment increased 8% to $92.4 million in the
second quarter and 5% to $170.2 million in the first six months of fiscal 2008 compared to the
corresponding periods last year.
Sales of Cardiac Assist products in the second quarter of fiscal 2008 increased 14%
year-over-year to $49.3 million due primarily to increased sales of balloon pumps (25%) and
the initial stocking order to our new distributor in Japan, which was partially offset by
reduced shipments to the former distributor. Sales of our Safeguard manual compression
assist product grew 14%. Favorable foreign exchange translation contributed $0.9 million to
Cardiac Assist sales in the second quarter of fiscal 2008. In the first six months of fiscal
2008, sales of Cardiac Assist products increased 4% to $88.9 million compared to $85.3
million last year due to the same reasons noted above.
Sales of Patient Monitoring products in the second quarter of fiscal 2008 increased 2% to
$43.1 million primarily due to Artema sales of gas modules, which are currently running at
an annualized rate of $11 million. Sales of central monitoring systems and bedside monitors
decreased 5%, primarily due to a strong second quarter last year which included several
large international orders. In addition, we believe certain customers are deferring
orders for capital equipment to future periods due to tightening credit markets. Favorable
foreign exchange translation contributed $0.7 million to patient monitoring sales in the
second quarter of fiscal 2008. In the first six months of fiscal 2008, sales of Patient
Monitoring products increased 6% to $81.3 million compared to $76.4 million last year
principally due to the same reason noted above.
23
Sales of the Interventional / Vascular Products segment were $10.7 million in the second quarter
of fiscal 2008 compared to $10.1 million last year and $19.8 million in the first six months of
fiscal 2008 compared to $20.5 million last year.
Sales of Interventional Products in the second quarter of fiscal 2008 were $1.2 million,
down 56% from $2.7 million last year as a result of the exit plan announced in October 2006.
Certain of our IP assets have been sold and we are in discussion to divest other IP assets.
We plan to seek the sale or independent distribution of our ProLumen thrombectomy device for
the interventional radiology market; although these plans are subject to the reversal of a
verdict in a pending appeal. Meanwhile, we continue to profitably service customer orders
for certain of our vascular closure products. In the first six months of fiscal 2008, sales
of Interventional Products decreased 59% to $2.5 million compared to $6.1 million last year.
Sales of InterVascular products in the second quarter of fiscal 2008 increased 28%
year-over-year to $9.5 million. The increase was principally due to sales of peripheral
vascular stent products obtained under a five-year exclusive distribution agreement with the
Sorin Group of Milan, Italy. As part of that agreement, we received an option to purchase
Sorins worldwide peripheral vascular stent business within two years of the agreement date.
Favorable foreign exchange translation contributed $0.5 million to patient monitoring sales
in the second quarter of fiscal 2008. In the first six months of fiscal 2008, sales were
$17.3 million, an increase of 20% compared to $14.4 million last year primarily due to the
same reason noted above.
Sales of vascular grafts increased 10% as a result of higher sales in certain international
markets, which helped to offset reduced sales to our exclusive U.S. distributor (28%).
Sales of Genisphere products were $0.3 million in the second quarter and $0.6 million in the
first six months of fiscal 2008 compared to $0.2 and $0.6 million, respectively, for the
corresponding periods last year.
Gross Profit (Net Sales Less Cost of Sales)
Gross profit increased $5.7 million, or 11%, in the second quarter and $3.9 million, or 4%, in
the first six months of fiscal 2008, primarily as a result of increased sales in the Cardiac
Assist / Monitoring Products segment ($7.1 million in the second quarter and $8.5 million in the
first six months of fiscal 2008).
Gross margin was 56.4% for the second quarter and 55.9% for the first six months of fiscal 2008
compared to 55.0% and 56.1%, respectively, for the corresponding periods last year. The higher
gross margin in the second quarter of fiscal 2008 compared to the same period last year was
principally due to a higher margin in the Cardiac Assist / Monitoring Products segment (2.4
points) as a result of a more favorable sales mix and an improved gross margin in the Patient
Monitoring business primarily resulting from manufacturing efficiencies and cost reduction
programs.
Research and Development Expense (R&D)
R&D expense includes new product development and improvements of existing products, as well as
expenses for regulatory filings and clinical evaluations. R&D expense was $9.6 million in the
second quarter of fiscal 2008, equivalent to 9.3% of sales, compared to $8.5 million, or 8.9% of
sales, for the same period last year. R&D expense was $18.6 million, equivalent to 9.8% of
sales, in the first six months of fiscal 2008 compared to $17.2 million, or 9.4% of sales, for
the same period last year.
24
R&D expense for the Cardiac Assist / Monitoring Products segment was $7.0 million in the second
quarter and $13.5 million in the first six months of fiscal 2008 compared to $5.9 million and
$11.9 million, respectively, in the corresponding periods last year. The increases were
primarily due to Artemas R&D expenses ($0.8 million in the second quarter and $1.4 million in
the first six months of fiscal 2008) and lower software development costs capitalized for
patient monitors, which increased R&D expenses compared to the prior year ($0.5 million in the
second quarter and $0.7 million in the first six months of fiscal 2008).
R&D expense for the Interventional / Vascular Products segment was $1.8 million in the second
quarter and $3.2 million in the first six months of fiscal 2008 compared to $2.0 million and
$4.0 million, respectively, in the corresponding periods last year. The decrease was primarily a
result of the IP exit plan ($0.7 million in the second quarter and $1.4 million in the first six
months of fiscal 2008), partially offset by higher expenses in InterVascular primarily for
product validation costs ($0.5 million in the second quarter and $0.6 million in the first six
months of fiscal 2008).
The balance of consolidated R&D is in Corporate and Other and amounted to $0.8 million in the
second quarter and $1.9 million in the first six months of fiscal 2008 compared to $0.6 million
and $1.3 million, respectively, in the corresponding periods last year. Corporate and Other R&D
includes corporate design, technology, regulatory and Genisphere R&D expenses.
Selling, General & Administrative Expense (SG&A)
Total SG&A expense increased 9% to $38.1 million, or 36.9% of sales, in the second quarter of
fiscal 2008 compared to $35.0 million, or 36.6% of sales, last year primarily attributable to
increased
corporate expenses ($1.3 million) principally related to the proxy contest, unfavorable
foreign currency translation ($1.1 million), Artemas expenses ($0.6 million) and
higher severance expenses ($0.5 million). Partially offsetting the above were
the cost reductions related to the IP exit plan and workforce reductions ($1.6
million). In the first six months of fiscal 2008, SG&A expense increased 2% to $71.6 million, or
37.6% of sales, compared to $70.1 million, or 38.4% of sales, for the same period last year.
SG&A expense for the Cardiac Assist / Monitoring Products segment increased $4.4 million, or
15%, to $33.0 million in the second quarter of fiscal 2008, primarily attributable to higher allocated corporate G&A charges ($2.5 million), Artemas expenses ($0.6
million), unfavorable foreign currency translation ($0.6 million), and higher severance
expenses ($0.5 million). In the first six months of fiscal 2008, SG&A expense increased $6.2 million, or 11%, to $62.4 million due to the same reasons noted
above. As a percentage of segment sales, SG&A expenses were 35.8% in the second quarter and
36.7% in the first six months of fiscal 2008 compared to 33.6% and 34.7%, respectively, in the
corresponding periods last year.
SG&A expense for the Interventional / Vascular Products segment decreased $0.7 million, or 11%,
to $5.9 million in the second quarter of fiscal 2008, primarily attributable to the cost savings
from the IP exit plan ($1.3 million), partially offset by unfavorable foreign currency
translation ($0.4 million). In the first six months of fiscal 2008, SG&A expense decreased $3.6
million, or 25%, to $10.8 million due primarily to the same reasons noted above. As a percentage
of segment sales, SG&A expenses were 55.4% in the second quarter and 54.1% in the first six
months of fiscal 2008 compared to 65.4% and 70.2%, respectively, in the corresponding periods
last year.
Segment SG&A expense includes allocated corporate G&A charges.
25
Interest Income
Interest income of $0.5 million in the second quarter of fiscal 2008 decreased $0.1 million
compared to the same period last year due to a decrease in the average portfolio balance ($43.9
million vs. $61.6 million) and a decrease in the interest rate yield to 4.3% from 4.7%. Interest
income was $1.1 million in the first six months of fiscal 2008 compared to $1.3 million last
year with the decrease due to the same reasons discussed above.
Gain on Sale of Investment
We had a preferred stock investment of $5.0 million in Masimo Corporation, a supplier to our
Patient Monitoring business. On August 13, 2007, Masimo completed its initial public offering,
and concurrently, we sold substantially all of our investment in Masimo, resulting in a pretax
gain on the sale of approximately $13.2 million in the first quarter of fiscal 2008.
Income Taxes
In the second quarter and first six months of fiscal 2008, the consolidated effective tax rate
was 35.0% and 37.6%, respectively, compared to 10.5% and 24.9% in the second quarter and first
six months last year, respectively. The higher tax rates in the fiscal 2008 periods were
primarily attributable to the higher tax rate on the gain on sale of investment in the first
quarter of fiscal 2008, expiration of the extraterritorial income exclusion on December 31, 2006
and a shift in the geographical mix of earnings to higher taxed jurisdictions. The lower tax
rates in the fiscal 2007 periods were primarily attributable to the higher tax rate benefit on
the $7.3 million second quarter fiscal 2007 special charges and the utilization of a foreign tax
loss carryforward (that had a valuation allowance) on the $1.3 million gain on sale of an
investment. Additionally, the second quarter and first six months of fiscal 2007 benefited from
retroactive recognition of the U.S. Research Credit. Our effective tax rate could be impacted by
changes in the geographic mix of our earnings.
Net Earnings
Net earnings were $7.1 million, or $0.46 per diluted share, in the second quarter of fiscal 2008
compared to $3.3 million, or $0.22 per diluted share, last year. Higher earnings in the second
quarter of fiscal 2008 were primarily attributable to increased earnings in the Interventional /
Vascular Products segment as a result of the cost reductions implemented last year and increased
earnings in the Cardiac Assist / Monitoring Products segment. Net earnings in the corresponding
period last year were impacted by the after-tax special charges of $4.7 million, or $0.30 per
diluted share, related to the IP exit plan and workforce reductions.
Net earnings were $18.9 million, or $1.22 per diluted share, in the first six months of fiscal
2008 compared to $7.9 million, or $0.51 per diluted share, for the same period last year. Higher
earnings in the first six months of fiscal 2008 were primarily attributable to the higher
after-tax gain on sale of investment this year ($6.5 million) and increased earnings in the
Interventional Products / Vascular Products segment as a result of the IP exit plan ($6.4
million), partially offset by the higher consolidated effective tax rate as discussed above.
Subsequent Event
On January 9, 2008, the Board of Directors declared a regular quarterly cash dividend of $0.10
per share, paid on February 8, 2008 to stockholders of record as of January 22, 2008.
26
Liquidity and Capital Resources
We consider our cash and cash equivalents, short-term investments and our available unsecured
lines of credit to be our principal sources of liquidity.
Cash and cash equivalents and short-term investments at December 31, 2007 were $42.8 million
compared to $39.4 million at June 30, 2007. Long-term investments were $15.4 million at December
31, 2007 compared to $14.3 million at June 30, 2007. Working capital was $149.3 million compared
to $147.3 million at the end of fiscal 2007 and the current ratio was 3.2:1 compared to 3.5:1 at
June 30, 2007.
The increase in working capital was primarily due to increases in accounts receivable ($6.7
million), cash and short-term investments ($3.3 million) and inventories ($2.9 million), offset
by an increase in accounts payable ($10.8 million). The lower current ratio was primarily
attributable to the increase in accounts payable.
The increase in accounts receivable was primarily due to increased sales. The increase in
inventories was primarily attributable to increased cardiac assist inventory for the EVH product
and build-up for the new Sensation 7.0 Fr. balloon. The increase in accounts payable was
primarily attributable to the higher inventory purchases.
In the first six months of fiscal 2008, we provided $18.0 million of net cash from operating
activities compared to $14.0 million last year with the increase primarily attributable to an
increase in accounts payable ($11.9 million), partially offset by decreased accounts receivable
($7.0 million).
We provided a net $3.2 million of cash from investing activities in the first six months of
fiscal 2008. Net sales and maturities of investments yielded $51.4 million. These proceeds were
spent on $40.2 million of investment purchases, $4.2 million of capital expenditures and
technology and $3.8 million of capitalized software.
We used $18.5 million of net cash from financing activities in the first six months of fiscal
2008. We paid $18.5 million in dividends, comprising two
quarterly dividend payments of $0.10 per
share and a special dividend of $1.00 per share, partially funded by $0.4 million of proceeds
from the exercise of stock options.
At December 31, 2007, we had available unsecured lines of credit totaling $99.5 million, with
interest payable at LIBOR-based rates determined by the borrowing period. Of the total
available, $49.0 million expires in March 2008 and $25.0 million expires in October 2008. These
lines of credit are renewable annually at the option of the banks, and we plan to seek renewal.
We also have $25.5 million in credit lines with no expiration date. We have approximately $1.0
million in letters of credit outstanding as security for inventory purchases from an overseas
vendor.
During the first six months of fiscal 2008, we did not repurchase any of our shares. We have a
remaining balance of $3.0 million available under the stock repurchase program authorized by the
Board of Directors on May 16, 2001.
On September 21, 2007, the Board of Directors declared a regular quarterly cash dividend of
$0.10 per share and a special dividend of $1.00 per share, both paid on October 15, 2007 to
stockholders of record as of October 1, 2007.
On September 12, 2006, the Board of Directors approved an additional stock repurchase program
for $40 million of our common stock. Purchases under this program may be made
27
from time to time on the on the open market or in privately negotiated transactions, and may be
discontinued at any time at our discretion.
We believe that our existing cash and investment balances, future cash generated from operations
and existing credit facilities will be sufficient to meet our projected working capital, capital
and investment needs. The moderate rate of current United States and European inflation has not
significantly affected us.
Information Concerning Forward Looking Statements
This Managements Discussion and Analysis of Financial Condition and Results of Operations
contains forward-looking statements that involve risks and uncertainties that could cause actual
results to differ materially from those projected in the forward-looking statements as a result
of many important factors. Many of these risks cannot be predicted or quantified and are at
least partly outside our control, including the risk that NetGuard does not have the potential
to create a new, significant market in monitoring currently unmonitored patients, that we are
not the first Company to address this market, that NetGuard will not be a significant
opportunity for new growth and that market conditions may change, particularly as result of
competitive activity in the markets served by the Company. Additional risks include the
Companys dependence on certain unaffiliated suppliers (including single source manufacturers)
for patient monitoring, cardiac assist and interventional products,
change in demand for the
Companys products, rapid and significant changes that generally characterize the medical device
industry and the ability to continue to respond to such changes and the uncertain timing of
regulatory approvals, as well as other risks detailed in documents filed by Datascope with the
Securities and Exchange Commission.
Critical Accounting Policies
Our financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America. The preparation of these financial statements requires
us to make estimates and assumptions that affect the reported amount of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amount of revenues and expenses for each period. We regularly evaluate our
estimates and assumptions on an on-going basis and adjust as necessary to accurately reflect
current conditions. These estimates and assumptions are based on current and historical
experience, on information from third party professionals and on various other factors that are
believed to be reasonable under the circumstances. Actual results could differ from those
estimates. Our critical accounting policies include Revenue Recognition, Allowance for Doubtful
Accounts, Inventory Valuation, Income Taxes and Pension Plan Actuarial Assumptions, as disclosed
in our Form 10-K for the fiscal year ended June 30, 2007.
28
Recent Accounting Pronouncements
On July 1, 2007, we adopted the provisions of the Financial Accounting Standards Board (FASB)
Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN 48), an interpretation
of Statement of Financial Accounting Standards (SFAS) No. 109, Accounting for Income Taxes.
FIN 48 clarifies the accounting for uncertainty in income taxes by prescribing that a benefit
cannot be recorded in the financial statements unless the tax position has a more likely than
not chance of being sustained upon audit based solely on the technical merits of the position.
Once the more likely than not standard is met, the benefit is measured by determining the
amount that is greater than 50 percent likely of being realized upon settlement, presuming that
the tax position is examined by the appropriate taxing authority that has full knowledge of all
relevant information. FIN 48 also provides guidance on derecognition, classification, interest
and penalties, accounting in interim periods, disclosure and transition. See Note 13 for
additional information related to the impact of adopting FIN 48.
In September 2006, FASB issued SFAS No. 157, Fair Value Measurements (SFAS 157). SFAS 157
defines fair value as: the price that would be received to sell an asset or paid to transfer a
liability in an orderly transaction between market participants at the measurement date. In
addition, SFAS 157 establishes a fair value hierarchy to be used to classify the source of
information used in fair value measurements, new disclosures of assets and liabilities measured
at fair value based on their level in the hierarchy and a modification of the long-standing
accounting presumption that the transaction price of an asset or liability equals its initial
fair value. SFAS 157 is effective in fiscal years beginning after November 15, 2007 (effective
for our fiscal year 2009 beginning July 1, 2008). The FASB has proposed a deferral of the
provisions of SFAS 157 relating to nonfinancial assets and liabilities that would delay
implementation by us until our fiscal year 2010 beginning July 1, 2009. SFAS 157 is not expected
to materially affect how we determine fair value, but may result in certain additional
disclosures.
In November 2006, the FASB issued Emerging Issues Task Force Issue No. 06-10, Accounting for
Deferred Compensation and Postretirement Benefits Aspects of Collateral Assignment Split-Dollar
Life Insurance Arrangements, which is effective for fiscal years that begin after December 15,
2007 (our fiscal year 2009 beginning July 1, 2008). The Task Force concluded that an employer
should recognize a liability for the postretirement benefit related to a collateral assignment
split-dollar life insurance arrangement in accordance with either FASB Statement No. 106,
Employers Accounting for Postretirement Benefits Other Than Pensions, or Accounting Principles
Board Opinion No. 12, Omnibus Opinion, based on the substantive agreement with the employee. The
Task Force also concluded that an employer should recognize and measure an asset based on the
nature and substance of the collateral assignment split-dollar life insurance arrangement. The
Supplemental Benefits Plan for the Chairman and Chief Executive Officer, Mr. Lawrence Saper,
provides survivor benefits in the form of a $10 million life insurance policy, maintained
pursuant to a collateral assignment split-dollar agreement among Mr. Saper, the Company and a
trust for the benefit of Mr. Sapers family. The present value of the premium reimbursement
pursuant to the split-dollar agreement at December 31, 2007 is approximately $3.4 million.
Upon adoption, we will record a liability and a cumulative effect adjustment to
retained earnings for the present value of the premium reimbursement at the date of
adoption.
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and
Financial Liabilities Including an amendment of FASB Statement No. 115. This statement
provides an option to report selected financial assets and liabilities at fair value. In
addition, SFAS 159 establishes presentation and disclosure requirements for those assets and
liabilities which the registrant has chosen to measure at fair value. SFAS 159 is
29
effective for fiscal years beginning after November 15, 2007 (our fiscal year 2009 beginning
July 1, 2008). We are currently evaluating the impact of adopting SFAS 159 on our consolidated
financial statements.
In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated
Financial Statements an amendment of ARB No. 51. This statement amends ARB 51 to establish
accounting and reporting standards for the noncontrolling interest in a subsidiary and for the
deconsolidation of a subsidiary. SFAS 160 clarifies a noncontrolling interest in a subsidiary is
an ownership interest in the consolidated entity that should be reported as equity in the
consolidated financial statements. SFAS 160 is effective for fiscal years beginning on or after
December 15, 2008 (our fiscal year 2010 beginning July 1, 2009). We are currently evaluating the
impact of adopting SFAS 160 on our consolidated financial statements.
In December 2007, the FASB issued SFAS No. 141(R), Business Combinations. This statement
establishes principles and requirements for how an acquirer recognizes and measures in its
financial statements the identifiable assets acquired, the liabilities assumed, the goodwill
acquired, and any noncontrolling interest in the acquiree. In addition, SFAS 141(R) establishes
disclosure requirements to enable the evaluation of the nature and financial effects of the
business combination. SFAS 141(R) applies prospectively to business combinations for which the
acquisition date is during fiscal years beginning on or after December 15, 2008, the effective
date of this statement. We will adopt SFAS 141(R) in the first quarter of our fiscal year 2010
beginning July 1, 2009.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Due to the global nature of our operations, we are subject to the exposures that arise from
foreign exchange rate fluctuations. Our objective in managing our exposure to foreign currency
fluctuations is to minimize net earnings volatility associated with foreign exchange rate
changes. We enter into foreign currency forward exchange contracts to hedge foreign currency
transactions which are primarily related to certain intercompany receivables denominated in
foreign currencies. Our hedging activities do not subject us to exchange rate risk because gains
and losses on these contracts offset losses and gains on the intercompany receivables hedged.
The net gains or losses on these foreign currency forward exchange contracts are included within
Other, net, in our condensed consolidated statements of earnings. We do not use derivative
financial instruments for trading purposes.
None of our foreign currency forward exchange contracts are designated as economic hedges of our
net investment in foreign subsidiaries. As a result, no foreign currency transaction gains or
losses were recorded in accumulated other comprehensive loss for the six-month periods ended
December 31, 2007 and 2006.
As of December 31, 2007, we had a notional amount of $18.5 million of foreign exchange forward
contracts outstanding, denominated in Euros and British pounds. The foreign exchange forward
contracts generally have maturities that do not exceed 12 months and require us to exchange
foreign currencies for United States dollars at maturity, at rates agreed to when the contract
is signed.
30
Item 4. Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information
required to be disclosed in our Exchange Act reports is recorded, processed, summarized and
reported within the time periods specified in the Securities and Exchange Commissions rules and
forms, and that such information is accumulated and communicated to the Disclosure Committee and
Companys management, including our Chief Executive Officer and Chief Financial Officer, as
appropriate, to allow timely decisions regarding required disclosure. In designing and
evaluating the disclosure controls and procedures, management recognizes that any controls and
procedures, no matter how well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives, and management necessarily is required to apply its
judgment in evaluating the cost-benefit relationship of possible controls and procedures.
We carried out an evaluation, under the supervision and with the participation of management,
including the Companys Chief Executive Officer and the Chief Financial Officer, of the
effectiveness of our disclosure controls and procedures as of the end of the period covered by
this report. Based on the foregoing, the Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures were effective.
During the quarter ended December 31, 2007, there were no changes in our internal control over
financial reporting that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.
31
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
We are subject to certain legal actions, including product liability matters, arising in the
ordinary course of our business. We believe we have meritorious defenses in all material pending
lawsuits. We also believe that we maintain adequate insurance against any potential liability
for product liability litigation. In accordance with generally accepted accounting principles we
accrue for legal matters if it is probable that a liability has been incurred and an amount is
reasonably estimable.
As noted in our Form 10-K for the fiscal year ended June 30, 2007, on March 18, 2005, Johns Hopkins
University and Arrow International, Inc. filed a complaint in the United States District Court for
the District of Maryland, seeking a permanent injunction and damages for patent infringement. They
allege that our ProLumen Rotational Thrombectomy System infringes the claims of their U.S. patents
5,766,191 and 6,824,551. We have filed an answer denying such infringement and discovery has been
completed. On October 13, 2006, Johns Hopkins and Arrow filed a second complaint based upon their
newly issued U.S. patent 7,108,704 claiming our ProLumen device infringes the claims of this
patent. The parties had agreed that this matter should be consolidated with the first case and the
consolidation has taken place. A jury trial took place in late
June 2007 resulting in a finding
that the ProLumen product infringed the three patents, a finding that we owed a $690 thousand royalty to the
plaintiffs, and the issuance of an injunction precluding us from
further selling the ProLumen product. We filed a Notice of Appeal
regarding the lower courts decision and subsequently filed an
Appellate Brief on October 12, 2007. The appellees filed a
Response Brief in November 2007. We believe we will be successful on appeal in overturning the lower courts
findings and, therefore, an accrual for the royalty liability has not been recorded and no
impairment of the assets related to ProLumen has been taken.
On December 6, 2007, The General Hospital Corporation and Welch Allyn Protocol, Inc.
filed an action for patent infringement against the Company in the United States District
Court for the District of Massachusetts. In their complaint, the Plaintiffs allege that the
Company has infringed and is infringing upon U.S. Patent No.
5,319,363 ( 363
Patent). The Plaintiffs further allege in their complaint that the infringing products
include products and accessories marketed and/or sold by the Company under its
Panorama, Passport, Passport 2 and Spectrum trade names and also alleges that other
products and accessories of the Company may also infringe the 363 Patent. The
complaint demands, among other things, a preliminary and permanent injunction against
the Company, damages and attorneys fees. While the complaint has not yet been formally
served upon the Company, the Company believes that it has meritorious
defenses to any
such claims and intends to defend this action vigorously.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table sets forth information on repurchases by the Company of its common stock
during the second quarter of fiscal year 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value of Shares |
|
|
|
Total |
|
|
|
|
|
|
Total Number of |
|
|
that May Yet Be |
|
|
|
Number of |
|
|
Average |
|
|
Shares Purchased as |
|
|
Purchased Under the |
|
|
|
Shares |
|
|
Price |
|
|
a Part of Publicly |
|
|
Programs |
|
Fiscal Period |
|
Purchased |
|
|
Per Share |
|
|
Announced Programs |
|
|
($ 000s) |
|
10/01/07 - 10/31/07 |
|
|
|
|
|
$ |
|
|
|
|
|
|
|
$ |
42,963 |
|
11/01/07 - 11/30/07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
42,963 |
|
12/01/07 - 12/31/07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
42,963 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
$ |
|
|
|
|
|
|
|
$ |
42,963 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The current stock repurchase programs were announced on May 16, 2001 and September 12, 2006.
Approval was granted for up to $40 million in repurchases for each program and there are no
expiration dates on the current programs.
32
Item 4. Submission of Matters to a Vote of Security Holders
The annual meeting of shareholders of Datascope
Corp. was held on December 20, 2007,
for the purpose of electing two Class I directors to hold office until the 2010 annual
meeting of shareholders and to ratify the appointment of Deloitte & Touche LLP as
the independent registered public accounting firm of Datascope Corp. for the fiscal year
ended June 30, 2008. David Dantzker, M.D. and James J. Loughlin were elected to serve
as Class I directors. Votes cast for the election of directors were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Election of Class I Directors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
William L. Asmundson |
|
For: |
|
|
5,682,610 |
|
|
Withheld: |
|
|
86,363 |
|
James J. Loughlin |
|
For: |
|
|
5,755,427 |
|
|
Withheld: |
|
|
13,546 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David R. Dantzker, M.D. |
|
For: |
|
|
7,814,992 |
|
|
Withheld: |
|
|
163,477 |
|
William J. Fox |
|
For: |
|
|
3,207,476 |
|
|
Withheld: |
|
|
4,770,993 |
|
The vote on the ratification of the appointment of Deloitte & Touche LLP as the independent
registered public accounting firm for the fiscal year ended June 30, 2008, was as follows:
|
|
|
|
|
For: 12,478,432 |
|
|
|
|
|
|
Against: |
8,252 |
|
|
|
Abstain: |
843,473 |
|
Alan B. Abramson, David Altschiller, Robert Klatell, Lawrence Saper and William W. Wyman
continued to serve as members of the Datascope Corp. Board of Directors after the annual
meeting.
Item 6. Exhibits
|
31.1 |
|
Certification of Principal Executive Officer Regarding Facts and Circumstances Relating
to Quarterly Reports |
|
|
31.2 |
|
Certification of Principal Financial Officer Regarding Facts and Circumstances Relating
to Quarterly Reports |
|
|
32.1 |
|
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002 |
33
Form 10-Q
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this Report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
|
|
|
|
DATASCOPE CORP.
Registrant
|
|
|
By: |
/s/ Lawrence Saper
|
|
|
|
Lawrence Saper |
|
|
|
Chairman of the Board and
Chief Executive Officer |
|
|
|
|
|
|
By: |
/s/ Henry M. Scaramelli
|
|
|
|
Henry M. Scaramelli |
|
|
|
Vice President, Finance and
Chief Financial Officer |
|
|
Dated: February 11, 2008